angiodynamics - ANGO
ANGO
Close Chg Chg %
6.95 -0.12 -1.73%
Closed Market
6.83
-0.12 (1.73%)
Volume: 389.72K
Last Updated:
Nov 22, 2024, 4:00 PM EDT
Company Overview: angiodynamics - ANGO
ANGO Key Data
| Open $7.00 | Day Range 6.79 - 7.04 |
| 52 Week Range 5.26 - 8.25 | Market Cap $282.41M |
| Shares Outstanding 40.63M | Public Float 38.75M |
| Beta 0.67 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$6.04 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 435.86K |
ANGO Performance
| 1 Week | 0.29% | ||
| 1 Month | 1.49% | ||
| 3 Months | -11.07% | ||
| 1 Year | -2.15% | ||
| 5 Years | -55.18% |
ANGO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
3
Full Ratings ➔
About angiodynamics - ANGO
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.
ANGO At a Glance
AngioDynamics, Inc.
14 Plaza Drive
Latham, New York 12110
| Phone | 1-518-795-1400 | Revenue | 303.91M | |
| Industry | Medical Specialties | Net Income | -184,349,000.00 | |
| Sector | Health Technology | Employees | 748 | |
| Fiscal Year-end | 05 / 2025 | |||
| View SEC Filings |
ANGO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.834 |
| Price to Book Ratio | 1.241 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -30.085 |
| Enterprise Value to Sales | 0.603 |
| Total Debt to Enterprise Value | 0.032 |
ANGO Efficiency
| Revenue/Employee | 406,302.139 |
| Income Per Employee | -246,455.882 |
| Receivables Turnover | 6.969 |
| Total Asset Turnover | 0.715 |
ANGO Liquidity
| Current Ratio | 2.12 |
| Quick Ratio | 1.455 |
| Cash Ratio | 0.834 |
ANGO Profitability
| Gross Margin | 46.609 |
| Operating Margin | -11.136 |
| Pretax Margin | -63.057 |
| Net Margin | -60.658 |
| Return on Assets | -43.361 |
| Return on Equity | -63.146 |
| Return on Total Capital | -87.163 |
| Return on Invested Capital | -57.523 |
ANGO Capital Structure
| Total Debt to Total Equity | 2.877 |
| Total Debt to Total Capital | 2.796 |
| Total Debt to Total Assets | 1.862 |
| Long-Term Debt to Equity | 1.916 |
| Long-Term Debt to Total Capital | 1.862 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Angiodynamics - ANGO
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 291.01M | 316.22M | 338.75M | 303.91M | |
Sales Growth
| +10.17% | +8.66% | +7.13% | -10.28% | |
Cost of Goods Sold (COGS) incl D&A
| 152.36M | 169.94M | 183.30M | 162.26M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 26.29M | 29.50M | 33.17M | 27.75M | |
Depreciation
| 8.16M | 10.04M | 14.38M | 14.70M | |
Amortization of Intangibles
| 18.14M | 19.46M | 18.79M | 13.05M | |
COGS Growth
| +15.42% | +11.54% | +7.86% | -11.47% | |
Gross Income
| 138.65M | 146.27M | 155.46M | 141.65M | |
Gross Income Growth
| +4.92% | +5.50% | +6.28% | -8.88% | |
Gross Profit Margin
| +47.65% | +46.26% | +45.89% | +46.61% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 151.78M | 164.15M | 173.68M | 174.42M | |
Research & Development
| 36.39M | 30.74M | 29.88M | 31.51M | |
Other SG&A
| 115.39M | 133.41M | 143.79M | 142.91M | |
SGA Growth
| +4.70% | +8.15% | +5.81% | +0.43% | |
Other Operating Expense
| 1.83M | 343.00K | 457.00K | 1.07M | |
Unusual Expense
| 20.32M | 10.25M | 32.50M | 213.09M | |
EBIT after Unusual Expense
| (35.28M) | (28.47M) | (51.18M) | (246.93M) | |
Non Operating Income/Expense
| 92.00K | (790.00K) | (554.00K) | 55.30M | |
Non-Operating Interest Income
| - | - | - | 1.61M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 861.00K | 688.00K | 2.70M | |
Interest Expense Growth
| - | -5.07% | -20.09% | +292.73% | |
Gross Interest Expense
| - | 861.00K | 688.00K | 2.70M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (36.05M) | (29.95M) | (54.44M) | (191.64M) | |
Pretax Income Growth
| +78.56% | +16.93% | -81.77% | -252.04% | |
Pretax Margin
| -12.39% | -9.47% | -16.07% | -63.06% | |
Income Tax
| (4.50M) | (3.40M) | (2.00M) | (7.29M) | |
Income Tax - Current - Domestic
| 100.00K | 120.00K | 129.00K | 318.00K | |
Income Tax - Current - Foreign
| 201.00K | 186.00K | 187.00K | 361.00K | |
Income Tax - Deferred - Domestic
| (3.38M) | (3.42M) | (207.00K) | (7.04M) | |
Income Tax - Deferred - Foreign
| (1.43M) | (293.00K) | (2.10M) | (929.00K) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (31.55M) | (26.55M) | (52.44M) | (184.35M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (31.55M) | (26.55M) | (52.44M) | (184.35M) | |
Net Income Growth
| +81.08% | +15.85% | -97.54% | -251.53% | |
Net Margin Growth
| -10.84% | -8.40% | -15.48% | -60.66% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (31.55M) | (26.55M) | (52.44M) | (184.35M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (31.55M) | (26.55M) | (52.44M) | (184.35M) | |
EPS (Basic)
| -0.8228 | -0.6805 | -1.3283 | -4.588 | |
EPS (Basic) Growth
| +81.27% | +17.29% | -95.19% | -245.40% | |
Basic Shares Outstanding
| 38.34M | 39.01M | 39.48M | 40.18M | |
EPS (Diluted)
| -0.8228 | -0.6805 | -1.3283 | -4.588 | |
EPS (Diluted) Growth
| +81.27% | +17.29% | -95.19% | -245.40% | |
Diluted Shares Outstanding
| 38.34M | 39.01M | 39.48M | 40.18M | |
EBITDA
| 11.33M | 11.28M | 14.49M | (6.10M) | |
EBITDA Growth
| +19.84% | -0.44% | +28.50% | -142.06% | |
EBITDA Margin
| +3.89% | +3.57% | +4.28% | -2.01% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 13.333 | |
| Number of Ratings | 3 | Current Quarters Estimate | -0.109 | |
| FY Report Date | 11 / 2024 | Current Year's Estimate | -0.401 | |
| Last Quarter’s Earnings | -0.11 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.38 | Next Fiscal Year Estimate | -0.24 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 3 | 3 |
| Mean Estimate | -0.11 | -0.11 | -0.40 | -0.24 |
| High Estimates | -0.10 | -0.11 | -0.40 | -0.23 |
| Low Estimate | -0.12 | -0.12 | -0.40 | -0.26 |
| Coefficient of Variance | -7.40 | -5.88 | -0.56 | -7.22 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Angiodynamics - ANGO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Angiodynamics - ANGO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 11, 2024 | Warren G. Nighan SVP Quality and Regulatory | 45,777 | Open market or private purchase of non-derivative security Non-derivative transaction at $6.09 per share | 278,781.93 |
| Oct 11, 2024 | Warren G. Nighan SVP Quality and Regulatory | 45,877 | Open market or private purchase of non-derivative security Non-derivative transaction at $6.08 per share | 278,932.16 |
| Jul 26, 2024 | James Christopher Clemmer President and CEO; Director | 637,405 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.13 per share | 4,544,697.65 |
| Jul 26, 2024 | James Christopher Clemmer President and CEO; Director | 634,033 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.13 per share | 4,520,655.29 |
| Jul 26, 2024 | Stephen A. Trowbridge EVP and CFO | 167,137 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.13 per share | 1,191,686.81 |
| Jul 26, 2024 | Stephen A. Trowbridge EVP and CFO | 166,470 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.13 per share | 1,186,931.10 |
| Jul 26, 2024 | Chad Thomas Campbell SVP/GM, Vascular Access | 63,982 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.13 per share | 456,191.66 |
| Jul 26, 2024 | Chad Thomas Campbell SVP/GM, Vascular Access | 63,587 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.13 per share | 453,375.31 |
| Jul 26, 2024 | Laura Piccinini SVP International | 38,465 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.13 per share | 274,255.45 |
| Jul 26, 2024 | Laura Piccinini SVP International | 38,052 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.13 per share | 271,310.76 |